팬젠

222110KOSDAQ의약품 제조업

56.8 / 100

Reference Date: 2026-07-24

Financial Score19.5 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly up 2.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Panzen focuses on producing and selling biosimilar EPO drugs, offering CMO/CDO services, and developing biopharmaceuticals such as Factor VIII and Aflibercept. Its EPO product, approved in Malaysia, South Korea, the Philippines, Saudi Arabia, and Thailand, has expanded globally. The company's proprietary PanGen CHO-TECH™ technology enhances biopharmaceutical production efficiency through advanced cell line and process development.

Number of Employees

78people

Average Salary

57.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

31.14Industry Average 11.230.0Point

2.8x industry avg (risky)

PBR

2.13Industry Average 0.810.0Point

2.6x industry avg (risky)

ROE

7.48Industry Average 4.015.5Point

1.9x industry avg (good)

Debt Ratio

0.10Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲46.0% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲85.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.9% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
팬젠 “신규 바이오시밀러 3종 연내 공정 수립”
팬젠이 연내 바이오시밀러 3종의 생산공정 수립을 완료함으로써 성장 기반을 확대하고 시장 경쟁력을 강화할 것으로 기대된다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 4,725Won52-week high 7,34052-week low 4,330

1-month return4.0Point

1m +2.83% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0